| Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. | |
| | |
MedLine Citation:
|
PMID: 17081084 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lowering blood pressure is the most effective treatment method to ensure a reduction in the total risk for cardiovascular morbidity and mortality. The renin-angiotensin system plays an important role in volume homeostasis and blood pressure regulation and is a target for several groups of pharmaceutical agents. Angiotensin II receptor blockers represent the newest class of antihypertensive compounds. They prevent the binding of angiotensin II to the subtype 1 receptor (AT(1)), which is believed to mediate most of the physiological actions relevant to the regulation of blood pressure. Telmisartan, a widely used AT(1) receptor antagonist, is a highly selective compound with high potency, a long duration of action and a tolerability profile similar to placebo. Numerous randomized clinical trials and community-based studies have demonstrated that oral telmisartan and combinations of telmisartan with hydrochlorothiazide are at least as effective in lowering blood pressure as all other hypertensive medications. This has been demonstrated in different populations of adult patients with mild-to-moderate essential hypertension, including patients with coexisting Type 2 diabetes, metabolic syndrome or renal impairment. Several large-scale, long-term, clinical endpoint studies are in progress to assess the beneficial effects of telmisartan on hypertension-related end-organ damage in patients at high risk of renal, cardiac and vascular damage whose blood pressure is well controlled. The most recent data from clinical trials and latest research regarding telmisartan will be reviewed in this article. |
| | |
Authors:
|
Matthias Goebel; Markus Clemenz; Thomas Unger |
Related Documents
:
|
10212374 - Target-organ damage and cardiovascular risk profile in resistant hypertension. influenc... 19636244 - Managing peripheral edema in patients with arterial hypertension. 22626994 - Prospective evaluation of systolic arterial pressure control with a phenylephrine infus... 1460354 - Medical treatment of critical limb ischaemia: encouraging results if candidates selecte... 4458944 - Influence of changes in heart rate, aortic pressure and flow rate upon experimental cor... 6440704 - The university of toronto head injury treatment study: a prospective, randomized compar... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 4 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-11-03 Completed Date: 2006-11-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 615-29 Citation Subset: IM |
Affiliation:
|
Universitätsmedizin Berlin, Center for Cardiovascular Research (CCR)/Institut für Pharmakologie und Toxikologie, Charité Campus Mitte, Charité--Hessische Str. 3-4 10115 Berlin, Germany. matthias.goebel@charite.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
metabolism,
pharmacokinetics,
pharmacology,
therapeutic use* Benzimidazoles / therapeutic use Benzoates / therapeutic use Diuretics / therapeutic use Drug Therapy, Combination Drug Toxicity Humans Hydrochlorothiazide / therapeutic use Hypertension / drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Diuretics; 144701-48-4/telmisartan; 58-93-5/Hydrochlorothiazide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing...
Next Document: Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease.